Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
暂无分享,去创建一个
F. Tubach | C. Brun-Buisson | L. Bouadma | B. Régnier | M. Wolff | C. Schwebel | B. Pasquet | S. Lasocki | J. Chastre | M. Dehoux | B. Veber | C. Luyt | F. Schortgen | C. Cracco | M. Bernard | Antonio Alvarez
[1] S. Pocock,et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.
[2] S. Marsch,et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study , 2009, European Respiratory Journal.
[3] T. Bregenzer,et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.
[4] B. Bein,et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial , 2009, Critical care.
[5] T. Fleming,et al. Issues in noninferiority trials: the evidence in community-acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] D. Gilbert,et al. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Briel,et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. , 2008, Archives of internal medicine.
[8] A. Gascoigne,et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy , 2008, The Journal of antimicrobial chemotherapy.
[9] A. Combes,et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia , 2008, Intensive Care Medicine.
[10] J. Pugin,et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. , 2008, American journal of respiratory and critical care medicine.
[11] K. Becker,et al. Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations , 2008, Critical care medicine.
[12] Sean Keenan,et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. , 2008, Journal of critical care.
[13] K. Colpaert,et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. , 2008, International journal of antimicrobial agents.
[14] R. Weinstein,et al. Acinetobacter infection. , 2008, The New England journal of medicine.
[15] P. J. Z. Teixeira,et al. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. , 2007, The Journal of hospital infection.
[16] Anthony S McLean,et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.
[17] J. Bartlett,et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Burke,et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .
[19] M. Christ-Crain,et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. , 2007, Chest.
[20] M. Christ-Crain,et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.
[21] Patrick Nicolas,et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.
[22] C. Weenink,et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.
[23] K. Wood,et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.
[24] Douglas G Altman,et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.
[25] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[26] A. Combes,et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. , 2005, American journal of respiratory and critical care medicine.
[27] A. MarioCalvo,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. A randomized trial. Chastre J, Wolff M, Fagon JY, Chevret S et al. JAMA 2003; 290: 2588-98 , 2004 .
[28] Marin H Kollef,et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. , 2004, Chest.
[29] M. Christ-Crain,et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.
[30] Michel Wolff,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.
[31] Djillali Annane,et al. Current epidemiology of septic shock: the CUB-Réa Network. , 2003, American journal of respiratory and critical care medicine.
[32] X. Panhard,et al. Emergence of Resistance in Normal Human Aerobic Commensal Flora during Telithromycin and Amoxicillin-Clavulanic Acid Treatments , 2003, Antimicrobial Agents and Chemotherapy.
[33] J. Quinn,et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. , 2003, JAMA.
[34] J. Quinn,et al. Antibiotic Resistance Among Gram-Negative Bacilli in US Intensive Care Units , 2003 .
[35] Marin H Kollef,et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.
[36] D. Pittet,et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. , 2001, American journal of respiratory and critical care medicine.
[37] M. Kollef,et al. Antibiotic Resistance in the Intensive Care Unit , 2001, Annals of Internal Medicine.
[38] Guidance for Industry E 10 Choice of Control Group and Related Issues in Clinical Trials , 2001 .
[39] T. Similowski,et al. Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.
[40] G Sherman,et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.
[41] L E Nilsson,et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. , 1999, JAMA.
[42] C. Sprung,et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.
[43] R A Weinstein,et al. Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. , 1996, JAMA.
[44] C. Sprung,et al. The ACCP-SCCM consensus conference on sepsis and organ failure. , 1992, Chest.
[45] K Y Liang,et al. Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.
[46] R. Austrian,et al. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. , 1964, Annals of internal medicine.